TriumphSpitSix wrote: This inactivity is pretty typical between phases. The 8/4 corporate update also indicated reporting progress "over the coming months" so seems we're in a lull for a while.
Just to help get things organized in my head, below are the upcoming catalysts as far as I can tell. Feel free to correct or add to these:
1. IND submission- Imminent?
2. IND "approval" - 30 days after submission (unless the FDA objects) it becomes effective and trial can proceed. I.e., we may not receive an express "approval" for the IND to start Phase III.
3. EO Ph2 meeting with FDA- "Prior to the start of the first Phase III trial"
4. Start of the first Phase III trial- "[N]ext spring" (late-March to May-ish?)
5. RoW licensing- Potential announcements anytime.
6. Announcement of "brand name" for OPX- Also anytime?
7. Report of preclinical studies for ATB-352- Also anytime?
8. NASDAQ uplisting- Hopefully after a nice pop from some of the above events since it will involve a reverse split. We would need 15:1 or 20:1 to do it now and that would not go over well with investors. Best to get us back to $.55 - $.60 (or higher) and do a 10:1 (or less.)
9. Sale of Citagenix- Anytime.
That's all I got!
woundedknee wrote:
Markets sometime gets bored with a stock like ATE, because it knows that the real deal is some time away and so the holders of the stock go elsewhere in the interim thinking they have time to get back in when the real deal takes place. Some stay and some go. Some win, because they stay, and some lose, because they weren't patient. Still long